<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikem.org/w/index.php?action=history&amp;feed=atom&amp;title=Mometasone_furoate%2FFormoterol_fumarate</id>
	<title>Mometasone furoate/Formoterol fumarate - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikem.org/w/index.php?action=history&amp;feed=atom&amp;title=Mometasone_furoate%2FFormoterol_fumarate"/>
	<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=Mometasone_furoate/Formoterol_fumarate&amp;action=history"/>
	<updated>2026-04-20T07:17:04Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.38.2</generator>
	<entry>
		<id>https://wikem.org/w/index.php?title=Mometasone_furoate/Formoterol_fumarate&amp;diff=229529&amp;oldid=prev</id>
		<title>ClaireLewis: /* References */</title>
		<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=Mometasone_furoate/Formoterol_fumarate&amp;diff=229529&amp;oldid=prev"/>
		<updated>2019-09-22T23:40:18Z</updated>

		<summary type="html">&lt;p&gt;&lt;span dir=&quot;auto&quot;&gt;&lt;span class=&quot;autocomment&quot;&gt;References&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 23:40, 22 September 2019&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l86&quot;&gt;Line 86:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 86:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;references/&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&amp;lt;references/&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[[Category:Pharmacology]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;[[Category:Pharmacology]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;[[Category:Pulmonology]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>ClaireLewis</name></author>
	</entry>
	<entry>
		<id>https://wikem.org/w/index.php?title=Mometasone_furoate/Formoterol_fumarate&amp;diff=111818&amp;oldid=prev</id>
		<title>Jonwarren: Creation of page</title>
		<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=Mometasone_furoate/Formoterol_fumarate&amp;diff=111818&amp;oldid=prev"/>
		<updated>2016-11-24T01:12:34Z</updated>

		<summary type="html">&lt;p&gt;Creation of page&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;==Administration==&lt;br /&gt;
*Type: [[Inhaled corticosteroid]]&lt;br /&gt;
*Dosage Forms: 100 mcg/5 mg/spray, 200 mcg/5 mcg/spray MDI&lt;br /&gt;
*Routes of Administration: Inhaled&lt;br /&gt;
*Common Trade Names: Dulera&lt;br /&gt;
&lt;br /&gt;
==Adult Dosing==&lt;br /&gt;
*Prior medium dose inhaled steroid&lt;br /&gt;
**2 puffs (100 mcg/5 mcg/spray) inhaled BID&lt;br /&gt;
***Max: 4 puffs/day&lt;br /&gt;
***Taper to lowest effective dose. Use shortest effective treatment duration.&lt;br /&gt;
*Prior high dose inhaled steroid&lt;br /&gt;
**2 puffs (200 mcg/5 mcg/spray) inhaled BID&lt;br /&gt;
***Max: 4 puffs/day&lt;br /&gt;
***Taper to lowest effective dose. Use shortest effective treatment duration.&lt;br /&gt;
&lt;br /&gt;
==Pediatric Dosing==&lt;br /&gt;
*12+ yo, prior medium dose inhaled steroid&lt;br /&gt;
**2 puffs (100 mcg/5 mcg/spray) inhaled BID&lt;br /&gt;
***Max: 4 puffs/day&lt;br /&gt;
***Taper to lowest effective dose. Use shortest effective treatment duration.&lt;br /&gt;
*12+ yo, prior high dose inhaled steroid&lt;br /&gt;
**2 puffs (200 mcg/5 mcg/spray) inhaled BID&lt;br /&gt;
***Max: 4 puffs/day&lt;br /&gt;
***Taper to lowest effective dose. Use shortest effective treatment duration.&lt;br /&gt;
&lt;br /&gt;
==Special Populations==&lt;br /&gt;
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C; Possible risk of teratogenicity in animal data at 0.3-8x MRHD. Possible risk of delayed ossification at 80x MRHD.&lt;br /&gt;
*[[Lactation risk categories|Lactation risk]]: L3; Safety unknown&lt;br /&gt;
&lt;br /&gt;
===Renal Dosing===&lt;br /&gt;
*Adult: Not defined&lt;br /&gt;
*Pediatric: Not defined&lt;br /&gt;
&lt;br /&gt;
===Hepatic Dosing===&lt;br /&gt;
*Adult: Not defined. Caution in hepatic impairment.&lt;br /&gt;
*Pediatric: Not defined. Caution in hepatic impairment&lt;br /&gt;
&lt;br /&gt;
==Contraindications==&lt;br /&gt;
*Allergy to class/drug&lt;br /&gt;
*[[Asthma]], acute&lt;br /&gt;
*Bronchospasm, acute&lt;br /&gt;
&lt;br /&gt;
==Adverse Reactions==&lt;br /&gt;
===Serious===&lt;br /&gt;
*Bronchospasm, paradoxical&lt;br /&gt;
*[[Asthma]] exacerbation&lt;br /&gt;
*Death, asthma-related&lt;br /&gt;
*Hypersenstivity reaction&lt;br /&gt;
*[[Anaphylaxis]]&lt;br /&gt;
*Adrenal Suppression&lt;br /&gt;
*Hypercorticism&lt;br /&gt;
*Growth suppression in peds pts&lt;br /&gt;
*[[Hypertension]]&lt;br /&gt;
*[[Hypotension]]&lt;br /&gt;
*[[Angina]]&lt;br /&gt;
*[[Cardiac arrest]]&lt;br /&gt;
*[[Arrhythmia]]&lt;br /&gt;
*[[Hypokalemia]]&lt;br /&gt;
*[[Hyperglycemia]]&lt;br /&gt;
*[[Glaucoma]] in long-term use&lt;br /&gt;
*Cataracts in long-term use&lt;br /&gt;
&lt;br /&gt;
===Common===&lt;br /&gt;
*Nasopharyngitis&lt;br /&gt;
*[[Headache]]&lt;br /&gt;
*[[Sinusitis]]&lt;br /&gt;
*[[Candidiasis]], oral&lt;br /&gt;
*[[Dysphonia]]&lt;br /&gt;
&lt;br /&gt;
==Pharmacology==&lt;br /&gt;
*Half-life: Mometasone: 5 hr. Formoterol: 10 hr.&lt;br /&gt;
*Metabolism: Mometasone: Liver, CYP450: 3A4 substrate. Formoterol: Liver extensively, CYP450: 2A6, 2C9/19, 2D6 substrate.&lt;br /&gt;
*Excretion: Mometasone: Feces 74%, Urine 8%. Formoterol: Urine 59-62% (10% unchanged), feces 32-34%.&lt;br /&gt;
&lt;br /&gt;
==Mechanism of Action==&lt;br /&gt;
*Mometasone: Exact mechanism of anti-inflammatory action unknown. Inhibits multiple inflammatory cytokines and produces multiple glucocorticoid and mineralcorticoid effects.&lt;br /&gt;
*Formoterol: Selectively stimulates beta-2 adrenergic receptors, relaxing airway smooth muscle.&lt;br /&gt;
&lt;br /&gt;
==Comments==&lt;br /&gt;
Black Box Warning: Long acting beta-2 adrenergic agonists (LABA) increase risk of asthma-related death. LABA use may increase risk of asthma-related hospitalization in pediatric and adolescent patients. Do not use corticosteroid/LABA combo if asthma adequately controlled on low-or medium-dose inhaled corticosteroids.&lt;br /&gt;
&lt;br /&gt;
==See Also==&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
[[Category:Pharmacology]]&lt;/div&gt;</summary>
		<author><name>Jonwarren</name></author>
	</entry>
</feed>